Since 2000, Singapore has invested heavily in biomedical sciences research and development, and these efforts are starting to bear fruit. This is particularly evident in the field of cancer, which has seen significant local contributions to improving outcomes of patients, substantial partnerships with pharmaceutical companies and the establishment of internationally known local companies. Today, Singapore has a strong critical mass of globally competitive basic and clinical research talent, state-of-the-art research and clinical infrastructure, and extensive connectivity to top centres around the world.
The Singapore Translational Cancer Consortium (STCC) is a nationally coordinated consortium to synergise cancer research capabilities in Singapore. Established in 2020, STCC aspires to bring Singapore’s cancer Research, Innovation and Enterprise capabilities to the next level of global competitiveness by leveraging existing strengths in cancer research and translation in a concerted manner across institutions in Singapore around a selected set of focus areas.
STCC represents a major opportunity for Singapore to be recognised as a global leader for selected Asian cancers in terms of research and translation capabilities, through building peaks of excellence and thought-leadership, and demonstrating healthcare and economic impact through its collaborative platforms and programmes.
To become a global leader for selected Asian cancers in research translation and its application to health and economic value creation.
To synergise the strongest basic, clinical and translational talent and expertise from across Singapore to create a cohesive and focused national-level cancer research and translational programme.